Sonnet Biotherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings Inc. is an American clinical-stage biotechnology company engaged in the development of innovative immunomodulatory drugs. It primarily aims to improve therapeutic outcomes for cancer patients by targeting the tumour microenvironment. The company conducts clinical trials in the US and Australia and collaborates with vendors in India, England, Germany, and Switzerland. Operating within the Healthcare sector, Sonnet BioTherapeutics Holdings Inc. leverages its proprietary Fully Human Albumin-Binding (FHAB™) platform. This approach seeks to enhance the efficacy and safety of treatments by delivering biologics to specific disease sites. Keep up to date on the latest share price changes by adding SONN stock to your eToro watchlist. This content was generated by artificial intelligence. We cannot guarantee the accuracy, completeness, or timeliness of the information provided.